Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » OncoCyte Enters Deal to Offer $7.6M in Stock

OncoCyte Enters Deal to Offer $7.6M in Stock

Jan 03, 2020
|
staff reporter

NEW YORK – Diagnostics firm OncoCyte said on Thursday that it has entered into definitive agreements with Pura Vida Investments, a healthcare focused registered investment advisor, and one other unnamed institutional investor, to purchase approximately $7.6 million of the company's common shares in a registered offering. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

And Now Serology Tests

A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?

German Shepherd's Own Sequence

A German shepherd called Nala has had her genome sequenced.

Young at Brain

Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.

Science Paper Examines Factors to Identify Metastatic Prostate Cancer Responsive to Checkpoint Inhibitors

In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.

What's Popular?

In Business News

  1. LexaGene Shifts Gears to Prepare Viral RT-qPCR Panel for FDA Emergency Submission

  2. Color Gears Up to Enter COVID-19 Testing Space

  3. Ipsum Diagnostics Coronavirus Test Gets FDA Emergency Use Authorization

  4. A. Menarini to Distribute Credo Diagnostics Coronavirus Assay Kit, Respiratory Infection Assays

  5. Amgen, Adaptive Biotechnologies Partner on Drug Discovery for COVID-19

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.